An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants

Study Identifier
P23-495
CT.gov Identifier
NCT05653986
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Migraine - General
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Reports meeting migraine diagnostic criteria consistent with International Classification of Headache Disorders (ICHD) (i.e., they report symptoms accompanying their headaches that meet migraine criteria22 at screening). * Currently using ubrogepant for acute treatment of migraine. * Experienced at least 3 migraine attacks in the last 30 days. * Currently taking atogepant for preventive treatment of migraine and has been taking atogepant, at the same dose, for at least 30 days.
    Exclusion Criteria:
    * Report currently taking Rimegepant (Nurtec®) for migraine treatment (acute or preventive). * Report currently taking any of the anti-CGRP mAbs for preventive treatment of migraine: * Erenumab (Aimovig®) * Galcanezumab (Emgality®) * Fremanezumab (Ajovy®) * Eptinezumab (Vyepti®)

    Protocol Summary

    Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will how effective the combination use of ubrogepant and atogepant is in treating adult participants with migraine. Change in migraine activity will be assessed.

    Urogepant (Ubrelvy) and Atogepant (Qulipta) are approved drugs for treatment of migraine in adults in the US. Approximately 432 adult participants who are prescribed Ubrogepant and atogepant by their doctors will be enrolled in this study in the United States.

    Participants will receive ubrogepant oral tablets and atogepant oral tablets as prescribed by their physician. Participants will be followed for 30 days.

    There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

    Study Locations

    Location
    Status
    Location
    Montefiore/Albert Einstein /ID# 252243
    The Bronx, New York, United States, 10461
    Status
    Not applicable